Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28365667 | 0.87 | CDC25A (0.62) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL18180209 | 0.86 | CDC25A (0.63) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL28370205 | 0.85 | CDC25A (0.67) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL28365737 | 0.84 | CDC25A (0.69) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL27379311 | 0.83 | PLA2G2A (0.49) | CDC25AALOX5CNR1CNR2MEN1 | |
| SCHEMBL9449574 | 0.82 | CDC25A (0.56) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL1520654 | 0.82 | ALOX5 (0.52) | ALDH1A1LMNAALOX5TBXAS1MEN1 | |
| SCHEMBL2187086 | 0.82 | L3MBTL1 (0.44) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL3743075 | 0.81 | CDC25A (0.70) | CDC25APLK1ALDH1A1LMNAMCL1 | |
| SCHEMBL2051630 | 0.80 | ALDH1A1 (0.80) | CDC25APLK1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | claimed |
| WO-1991016360-A1 | COMPOSITIONS CONTAINING ORGANIC-SOLUBLE XANTHENE DYE PHOTOINITIATORS | OLIN CORPORATION (US) | 1991-10-31 | — | — | WO | claimed |
| EP-2343285-B1 | Peptoid compounds useful as antibiotics | UNIV WOLLONGONG (AU) | 2015-02-25 | — | — | EP | disclosed |
| US-8481587-B2 | Substituted 2-(5-hydroxy-2-methyl-1H-indole-3-yl)acetic acids and ethers thereof and the use of same to treat viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2013-07-09 | — | — | US | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | disclosed |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | ALLA CHEM, LLC. | 2011-09-22 | — | — | US | disclosed |
| EP-2343285-A2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-07-13 | — | — | EP | disclosed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | disclosed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0620214-B1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | LILLY CO ELI (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5578634-A | SEPTIC SHOCK TREATMENT | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0620214-A1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5100928-A | Toners for electrography, light sensitive coatings and films | OLIN CORPORATION (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991016360-A1 | COMPOSITIONS CONTAINING ORGANIC-SOLUBLE XANTHENE DYE PHOTOINITIATORS | OLIN CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108499-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | CDC25A 947/4885PLK1 918/4885ALDH1A1 4540/4885 |
| US-20100167995-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | CDC25A 947/4885PLK1 918/4885ALDH1A1 4540/4885 |
| US-20110230524-A1 | SUBSTITUTED 2-(5-HYDROXY-2-METHYL-1H-INDOLE-3-YL)ACETIC ACIDS AND ETHERS THEREOF AND THE USE OF SAME TO TREAT VIRAL DISEASES | IDO1, TPH1, FOXM1 | CDC25A 691/4885PLK1 4604/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.